bioAffinity Technologies Appoints Three New Medical and Scientific Advisory Board Members

robot
Abstract generation in progress

bioAffinity Technologies has expanded its Medical and Scientific Advisory Board with the appointment of three new members: Drs. David Ost, Daniel Sterman, and J. Scott Ferguson. These appointments aim to align the board with the company’s clinical, scientific, and commercial priorities, particularly for its noninvasive lung cancer diagnostic test, CyPath Lung. The new members are highly respected leaders in pulmonary medicine and lung cancer care, and their expertise will support the integration and adoption of CyPath Lung for early lung cancer detection.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin